Trials / Conditions / Stage 0a Bladder Cancer AJCC v8

Stage 0a Bladder Cancer AJCC v8

12 registered clinical trials studyying Stage 0a Bladder Cancer AJCC v8 — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Act NCT07302230	University of Washington	N/A
Recruiting	A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With NCT06733363	Roswell Park Cancer Institute	Phase 2
Recruiting	Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-M NCT07000084	Alliance for Clinical Trials in Oncology	Phase 3
Recruiting	In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial NCT06704191	Mayo Clinic	Phase 1 / Phase 2
Recruiting	PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle I NCT06173349	University of California, Davis	Phase 1
Recruiting	IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for NCT05843448	University of California, Davis	Phase 1
Completed	Behavioral Dietary Intervention for the Improvement of Bladder Cancer Survivorship NCT04548193	Roswell Park Cancer Institute	Phase 1
Completed	Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Blad NCT04496219	Fred Hutchinson Cancer Center	Phase 2
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment ( NCT04164082	National Cancer Institute (NCI)	Phase 2
Completed	Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes NCT04501913	City of Hope Medical Center	—
Active Not Recruiting	Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study NCT06350734	Mayo Clinic	—
Completed	Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer NCT00749892	M.D. Anderson Cancer Center	Phase 2